CITY-OF-TAMPERE
20.5.2021 10:17:12 CEST | Business Wire | Press release
The competition entry Lumen Valo has won the international architectural competition for the new Sara Hildén Art Museum building in Tampere, Finland. The winning entry was designed by architect Janne Hovi. The new art museum will be located in the former industrial milieu at the city centre.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210520005014/en/
- Competition entry Lumen Valo takes into account, by simple means, both the values related to the history of the Finlayson area and the starting points of the surrounding area and the requirements of the art, says the chair of the jury, Deputy Mayor Jaakko Stenhäll.
A total of 472 entries were approved for the competition, which is among the highest in the history of Finnish architectural competitions.
According to the jury, aesthetics that fit the spirit of the Finlayson industrial area and Sara Hildén Art Museum is captured in the subtle design of the winning competition entry Lumen Valo. In its matter-of-factness, it relates to the historical architecture of the construction site.
According to the jury, the winning competition entry continues the tradition of the area, where buildings have been built based on the needs of their purpose. The overall shape has been derived from the exhibition facilities. In this, the winning competition entry truly stands out from among the rest.
The other entries that ranked in the competition are Obscura by Heljä Nieminen and Havu Järvelä and Mezzo by Arkkitehdit Rudanko + Kankkunen Oy that came in shared third place. Entries XXX (Arquitectos Ayala S.L.P.) and A sculpture in the park (ALL – atelier lorentzen langkilde) were purchased. In addition, ten entries were given an honorary mention.
The competition aimed to create an architecturally distinctive building that would take account of the values of its environment, create a framework for art, and support the identity and character of the Sara Hildén Art Museum.
The competition was organised by Varma Mutual Pension Insurance Company, Sara Hildén Foundation, and the City of Tampere in cooperation with the Finnish Association of Architects (SAFA).
Link to the competition website:
https://www.sarahildenkilpailu.fi/
English website of the City of Tampere:
https://www.tampere.fi/en/index.html
Sara Hildén Art Museum:
https://www.tampere.fi/sarahilden/en/index.html
Finlayson area:
https://www.finlaysoninalue.fi/en/
View source version on businesswire.com: https://www.businesswire.com/news/home/20210520005014/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 10:22:00 CET | Press release
Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release
- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur
Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
